Experimental medicinal hepatitis. Hepatoprotective effects of the drug Laennec in models of toxic liver injury with paracetamol or alcohol

Author:

Gromova O. A.1ORCID,Torshin I. Yu.1ORCID,Demidov V. I.2,Zhidomorov N. Yu.2ORCID,Kalacheva A. G.2ORCID,Bogacheva T. E.2ORCID,Grishina T. R.2ORCID

Affiliation:

1. Federal Research Center Computer Science and Control, Russian Academy of Sciences

2. Ivanovo State Medical Academy

Abstract

Hepatoprotectors are necessary for the treatment of alcoholic and non-alcoholic (including medicinal) liver damage. This paper presents the results of a study of the Laennec hepatoprotector, produced on the basis of pharmaceutically standardized human placental hydrolysates (HPH). The use of HSP in toxic liver damage with alcohol or paracetamol led to a significant decrease in markers of liver dysfunction (AST, ALT, bilirubin, MDA), which increase when the models are reproduced. The hepatoprotective effect of Laennec was confi rmed by the results of histological studies, indicating a reduction in infl ammation and preservation of the liver parenchyma. Histological studies also indicated the nephroprotective and cardioprotective effects of Laennec in liver damage with both alcohol and paracetamol.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference14 articles.

1. Reference book of medicines Vidal. Moscow. AstraPharmService, 2021, 1298 P. (in Russ.)

2. Gromova O.A., Torshin I. Yu., Zgoda V. G., Tomilova I. K. Molecular mechanisms of action of the drug Laennec against the formation of metabolic syndrome and obesity. Th erapy. 2017. No. 5. pp. 73–83. (in Russ.)

3. Tohda C., Kogure C., Nomoto K., de Toledo A., Yang X., Hirano E. A Novel Heptapeptide, GPPGPAG Transfers to the Brain, and Ameliorates Memory Dysfunction and Dendritic Atrophy in Alzheimer’s Disease Model Mice. Front Pharmacol. 2021;12:680652. Published 2021 May 14. doi:10.3389/fphar.2021.680652

4. Maksimov V. A., Torshin I. Yu., Chuchalin A. G., Lazebnik L. B., Tkacheva O. N., Strazhesko I. D., Gromova O. A. Efficacy and safety of the polypeptide drug (Laennec) in therapy for COVID-19. Experimental and clinical gastroenterology. 2020;178(6): 55–63. (in Russ.) doi: 10.31146/1682–8658-ecg-178–6–55–63

5. Sayfutdinov R. R., Maksimov V. A., Khasanov R., Akhmedov R. U., Salyakhova E. V., Sayfutdinov R. G. Possibilities of Using Placenta Hydrolysate in Patients with COVID-19. EC Gastroenterology and Digestive System. 2021;8(11): 91–101. (in Russ.)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Pharmacological models of liver iron overload;Experimental and Clinical Gastroenterology;2024-03-15

2. Study of the effectiveness of the drug Laennek in case of liver damage by palm oil in rats;Pharmacokinetics and Pharmacodynamics;2024-01-22

3. Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3